Table 1.
Baseline characteristics and concomitant treatment of the two groups, with and without additional treatment after initial CE.
| Treatment change | Yes | No | |
|---|---|---|---|
| n = 86 | n = 39 | ||
| Gender (no. of patients) (%) | |||
| Male | 62 (72.1) | 28 (71.8) | |
| Female | 24 (27.9) | 11 (28.2) | |
| Age (years) | Median (range) | 38.5 (14–80) | 37 (14–67) |
| Disease duration (years) | Median (range) | 9 (0–43) | 9 (0–26) |
| Disease type (no. of patients) (%) | |||
| Ileitis type | 46 (53.5) | 20 (51.3) | |
| Ileocolonic type | 40 (46.5) | 19 (48.7) | |
| Previous surgery (no. of patients) (%) | |||
| None | 29 (33.7) | 19 (48.7) | |
| >1 | 57 (66.3) | 20 (51.3) | |
| Perianal lesion (no. of patients) (%) | |||
| None | 49 (57.0) | 19 (48.7) | |
| Yes | 37 (43.0) | 20 (51.3) | |
| Indications for CE (no. of patients) (%) | |||
| Symptom | 21 (24.4) | 11 (28.2) | |
| Monitoring | 65 (75.6) | 28 (71.8) | |
| CDAI | Mean (SD) | 94.4 (55.6) | 123.1 (86.6) |
| Serum albumin level (g/dl) | Mean (SD) | 4.2 (0.4) | 3.7 (0.7) |
| Serum CRP level (mg/dl) | Mean (SD) | 0.19 (0.4) | 0.87 (1.9) |
| Lewis score | Median (range) | 135 (0–4128) | 450 (0–3922) |
| Stenosis score | 0 | 79 | 27 |
| 196–400 | 6 | 5 | |
| 2352– | 1 | 7 | |
| Medications (no. of patients) (%) | |||
| 5ASA | 77 (89.5) | 34 (87.2) | |
| Elemental diet | 49 (57.0) | 29 (74.4) | |
| Immunomodulator | 16 (18.6) | 9 (23.1) | |
| Anti-TNF agent | 61 (70.9) | 25 (64.1) |
CDAI: Crohn's disease activity index; CRP: C-reactive protein.